Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant sale of 93,844,335 shares on November 4, 2025, at a price of $931.25 per share. This transaction amounted to a total value of approximately $87.39 billion.
Following this sale, Lilly Endowment Inc retains the same number of shares in the company, indicating a potential strategy behind the transaction. Insider sales can occur for a variety of reasons, including diversification, tax planning, or personal financial needs. While large sales may attract attention, they do not inherently signal negative sentiment toward the company.
Eli Lilly & Co, headquartered in Indianapolis, Indiana, is a key player in the pharmaceuticals industry, employing around 47,000 full-time staff. The firm is known for its extensive portfolio, which includes cardiometabolic health products such as Humalog and Trulicity, oncology products like Verzenio, and immunology treatments including Taltz.
As of November 8, 2025, Eli Lilly's market capitalization stands at $886.2 billion, with a trailing P/E ratio of 48.13 and an EPS of 20.45. The company has an upcoming earnings report scheduled for August 4, 2026, with an estimated EPS of $7.70 and projected revenue of $17.9 billion.
Investors are advised to consider insider transactions as one of many factors in their analysis. Patterns of activity across multiple insiders may provide more comprehensive insights than isolated transactions.